Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BP-011
- Development stage
- Preclinical
- Lead developer
- Brillian Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BP-011 is a pediatric reformulation of an existing cholesterol-lowering (lipid-lowering) medication developed by Brillian Pharma. It utilizes the company's proprietary "Unidose" technology, which converts traditional dosage forms into child-friendly formats such as oral solutions or lyophilized powders for reconstitution. This delivery platform is designed to ensure precise single-dose administration and improve treatment adherence in pediatric patients. While the specific active pharmaceutical ingredient (API) has not been publicly disclosed, the product is categorized within the lipid-lowering therapy class, targeting the management of elevated cholesterol levels in children.
Beyond the preview
Go deeper on BP-011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BP-011.